Although there has been promising data regarding the usage of FLT3 inhibitors in combination with azacytidine for the management of FLT3-ITD+ in AML patients, these inhibitors have not improved survival to the same level as imatinib in managing CML or ATRA in managing acute promyelocytic leukaemia (APL). Here, FLT3 is linked to acute promyelocytic leukemia.